Life-changing therapies for chronic disease states.
Altanova is quality-led, not grower-led. We operate exclusively in the regulated medical channel. We do not market to patients, we do not operate in the recreational market, and we do not maintain any consumer or wellness adjacencies anywhere in our corporate structure.
Altanova runs a Swissmedic-aligned quality system anchored by Responsible Person and Qualified Person functions; qualified EU-GMP supply relationships across multiple jurisdictions; and a specialty-pharma medical-channel infrastructure built for pharmacies, hospital formularies and physicians.
Our work is institutional rather than promotional. Our governance is sized to the standard expected of a Swiss specialty pharmaceutical company preparing for institutional investment and, in time, a strategic exit to a specialty-pharma acquirer.
Read about our leadership →Institutional operating standards.
Michael Porter
Founder & Executive Chairman, Altanova Pharma Group AG
Michael Porter is Founder and Executive Chairman of Altanova Pharma Group AG and principal of MWP Family Office / PG Equity Group in Zug, Switzerland. He is an operator-investor with more than two decades of experience building, acquiring and scaling regulated healthcare, specialty pharmaceutical and life sciences platforms across the United States, Europe and international markets.
Michael was previously Founder and Chief Executive Officer of Covis Pharma, a global specialty pharmaceutical company backed by Cerberus Capital Management & Apollo Management. During his tenure, Covis completed 23 M&A transactions, scaled into a top 10 global multi-country commercial platform selling into over 55 countries, executed three monetization events and distributed more than $1.5 billion in profit to investors.
Governance Principles
- • Swiss board-level governance with clear segregation of roles and institutional transparency.
- • Formally appointed management and specialized advisors across relevant medical, regulatory, and supply domains.
- • Quality and regulatory systems oversight anchored by non-delegable Responsible Person and Qualified Person functions.